© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
GI Cancers | Clinical
Paradigm Pivots in Neoadjuvant Direction: Expert Insights on World Pancreatic Cancer Day
November 19, 2020
Following a long history with minimal advances, neoadjuvant therapy provides hope on future avenues to further explore in order to continue improving outcomes for patients with pancreatic cancer.
Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors
November 17, 2020
In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.
Marshall Recognizes Need for Collaboration During Pancreatic Cancer Awareness Month
November 13, 2020
In an interview with Targeted Oncology, John L. Marshall, MD, provided an overview of the evolution of treatments for patients with pancreatic cancer, as well as the current therapeutic approaches for these patients and what’s next for this treatment paradigm.
First-In-Class Targeted Therapy Shows Survival Benefit Advanced Gastric/GEJ Adenocarcinoma Subset
November 11, 2020
Three efficacy end points met pre-specified statistical significance in the phase 2 FIGHT study of bemarituzumab plus modified FOLFOX6 in patients with FGFR2b-positive non-HER2-positive frontline advanced gastric or gastroesophageal junction cancer.
Irinotecan Monotherapy Appears as Efficacious as Capecitabine Combo in Advanced Gallbladder Cancer
November 11, 2020
In an interview with Targeted Oncology, Anant Ramaswamy, MD, discussed the findings from the phase 2 study of capecitabine plus irinotecan compared with irinotecan alone as treatment of patients with advanced gallbladder cancer.
FDA Grants Fast Track Designation to CPI-613 in Metastatic Pancreatic Cancer
November 10, 2020
The FDA has granted a Fast Track designation to CPI-613 for the treatment of metastatic pancreatic cancer.
New and Updated Data in GI Cancer Trials Show Continued Benefit With Targeted and Immunotherapy Agents
October 26, 2020
Historically, in gastrointestinal malignancies, chemotherapy and radiation were utilized to improve outcomes for patients. Although these treatments were effective, disease recurrence was always imminent, demonstrating a need for novel therapies.
Laber Evaluates Therapeutic Options by Lines of Therapy in GI Cancers
October 16, 2020
During Case Based Peer Perspectives event, Damian Laber, MD, discussed the case of a 53-year-old male patient with stage IV colorectal cancer.
FDA Grants Orphan Drug Designation to Novel Monoclonal Antibody in Multiple GI Malignancies
October 15, 2020
An Orphan Drug Designation had been granted by the FDA to the CD40 antagonistic monoclonal antibody, APX005M for the treatment esophageal and gastroesophageal junction cancer, as well as for the treatment of patients with pancreatic cancer.
Expert Highlights Importance of Biomarker Testing in Pancreatic Cancer
October 07, 2020
At ISGIO 2020, Michael J. Pishvaian, MD, PhD, discussed the importance of using standard-of-care chemotherapy and to test for actionable mutations in patients with pancreatic cancers, which can identify ways to individualize therapy for these patients.